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Wnt SignalingThe Wnt signaling pathway was identiﬁed as crucial mediator of cardiomyocyte hypertrophy. In this
study we found that activation of non-canonical Wnt signaling by Wnt5a stimulates protein synthe-
sis and enlargement of cardiomyocyte surface area. These hypertrophic features were inhibited in
Dapper-1 (Dpr1) depleted cells. On the molecular level, we observed inhibition of the non-canonical
Wnt/planar-cell-polarity (PCP) pathway denoted by reduction of c-jun-n-terminal-kinase (JNK)
phosphorylation. Upstream of JNK, increased protein levels of the Wnt/PCP trans-membrane recep-
tor van-Gogh-like-2 (Vangl2) were observed along with an enrichment of Vangl2 in perinuclear
located vesicles. The ﬁndings suggest that Dpr1 is essential for execution of the Wnt/PCP pathway
and regulation of the Vangl2/JNK axis. Depletion of Dpr1 inhibits non-canonical Wnt signaling
induced cardiomyocyte hypertrophy by blocking Wnt/PCP signaling.
Structured summary of protein interactions:
Dpr1 and Vangl2 colocalize by ﬂuorescence microscopy (View interaction)
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction (Fzd) receptors, receptor-tyrosine-kinase-like-orphan-receptorCardiac hypertrophy is an adaptive response to balance the
increased workload of the heart in state of pathological stress. It
is mainly characterized by increased protein synthesis and an
enlargement of single cardiomyocytes [1]. The contribution of
Wnt signaling in the development of cardiac diseases is increas-
ingly recognized in basic cardiovascular research [2–5]. Generally,
the Wnt signaling pathway is differentiated between the canonical
and the non-canonical branch [6,7]. Both pathways require Wnt
ligand binding to membrane receptors and Dishevelled (Dvl)
activity in the cytoplasm [8,9]. Canonical and non-canonical
pathways recruit different downstream proteins to transduce
Wnt signals. The non-canonical pathway is separated into
three branches: the planar-cell-polarity (PCP) pathway, the
Ca2+/calmodulin-dependent-protein-kinase-2 pathway (CamKII),
and the protein-kinase-C (PKC) pathway [10]. Among the Frizzled(ROR2) in conjunction with van-Gogh-like-2 (Vangl2) mediates the
transmission of extracellular signals by binding Wnt ligands [11].
Following ligand/receptor binding, Dvl proteins are crucial coordi-
nators of signal transduction in all non-canonical branches. Dpr1
interacts with Dvl in cell and context dependent manner [12,13].
Previous studies allocated a functional role of both proteins in the
Wnt/PCP pathway which is activated through the ROR2/Vangl2/
c-jun-terminal-kinase-1(JNK) axis [11]. In a recentlypublishedwork
we have demonstrated that over-expression of theWnt component
Dapper-1 (Dpr1) in a transgenic mouse model activates canonical
Wnt signaling in a Dishevelled-2 (Dvl2) dependent manner and
induces cardiac hypertrophy [12]. Although in cardiomyocytes
Dpr1 is an activator of canonical Wnt signaling its role in non-
canonicalWnt signaling is not investigated to date. Here,we address
the role of Dpr1 in non-canonical Wnt signaling transduction.
We provide evidence that Dpr1 is essential to activate the
non-canonical Wnt/PCP pathway in cardiomyocytes. Moreover,
we demonstrate that Wnt5a induced activation of the Wnt/PCP
pathway induces cardiomyocyte hypertrophy and that Dpr1
depletion inhibits cells from hypertrophic growth by interruption
of the Vangl2/JNK axis.
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2.1. Cardiomyocytes culture and determination of myocyte surface
area
Isolation and culture of cardiac myocytes was performed as
described previously [14]. For determination of surface area
cardiomyocytes were cultured on coverglasses and transfected
with siRNA as described [14] or incubated with JNK Inhibitor
SP600125 [10 lM] or DMSO as a control. 48 h later (for siRNA
treated cells) or 1 h later (for SP600125 treated cells) cells were
stimulated with Wnt5a conditioned medium (1:50 dilution) for
further 2 days. Myocytes were washed twice with ice cold
phosphate-buffered saline and ﬁxed in PBS containing 4% parafor-
maldehyde for 30 min. For permeabilization cell membrane cells
were incubated for 10 min in phosphate-buffered saline containing
0.1% Triton X. Fixed cells were blocked with 2% BSA in phosphate-
buffered saline for 1 h. Immunostaining was performed using
Texas Red phalloidin (Molecular Probes) and DAPI staining for
30 min. After staining coverglasses were ﬁxed on microscope slides
and microscope images were captured by a digital camera.
Myocyte surface area from at least 100 cells per group in each
experiment, were analyzed by using the Image J program.
2.2. RNA analysis
Quantitative real-time PCR was performed as described previ-
ously [14]. Real time PCR was performed using the Universal Probe
Library from Roche Diagnostics. Primers and Probes used are HPRT
50-GTCAAGGGGGACATAAAAG-30 and 50-TGCATTGTTTTACCAGTGT
CAA-30, probe #22; Vangl2 50-GCGAGCCGCTTCTATAATGT-30 and
50-TCTCCAGGATCCACACTGC-30, probe #42.
2.3. siRNA transfection
Cardiomyocytes were cultured in serum and antibiotic free
medium for at least 5 h. For transfection of 2  106 cardiomyocytes
in a 6 cm dish 250 pmol siRNA was diluted in 650 lL serum- and
antibiotic free OptiMEM (Invitrogen). In another tube 4.5 lL of
Lipofectamin 2000 (Invitrogen) was diluted in 200 lL OptiMEM
and incubated for 15 min. After complex formation the solution
and OptiMEM were added to the cells. The cells were incubated
for 72 h at 37 C. siRNAs used were Dpr1 50-GCAGAUAAGUGACCU
GAGA-30 and non-speciﬁc control siRNA 50-AGGUAGUGUAAUC
GCCUUGTT-30. In all siRNA mediated knockdown experiments
myocytes transfected with non-speciﬁc (scrambled) siRNA were
used as controls. siRNAs were synthesized by MWG (Ebersberg,
Germany). Knockdown of Dpr1 was conﬁrmed byWestern blotting.
2.4. Adenoviral infection of isolated cardiomyocytes
Cardiomyocytes were cultured with serum free medium. The
next day cardiomyocytes were infected over night with adenovirus
encoded Dpr1 (Applied Biological Materials Inc., Richmond,
Canada) or an empty adenovirus vector as a control. After washing
the cells 3 times with PBS the culture medium was changed. 48 h
later protein lysates were prepared. Overexpression of Dpr1 was
conﬁrmed by Western blotting.
2.5. Protein analysis
Immunoblot analyses were performed as described previously
[14]. Primary antibodies used were anti-Dapper1 (Santa Cruz, for
rat), anti JNK1 (Santa Cruz), anti phospho-SAPK/JNK (Thr183/185)
(Cell signaling), anti-CaMKII (BD Transduction Laboratories),anti-ActiveCaMKII (Thr286) (Promega), PKCa (Cell Signaling),
phospho-PKCa/bII (Thr 638/641) (Cell Signaling), anti-Vangl2
(Santa Cruz). Anti-a-actin (Sigma–Aldrich) and anti-GAPDH
(US-biological). Horseradish peroxidase-conjugated Anti-rabbit
IgG, anti-mouse IgG and anti-goat IgG antibodies (Santa Cruz)
were used as secondary antibodies. Bands were quantiﬁed by
densitometry using the Image J program.
2.6. [3H]-Glycine incorporation assay
Cardiomyocytes were cultured in 12 well plates. The next day
cells were transfected with Dpr1 speciﬁc siRNA for 48 h or incu-
bated with JNK inhibitor SP600125 [10 lM] for 1 h. Then, cells
were stimulated with Wnt5a conditioned medium (1:50 dilution)
and incubated with 1 lCi/ml [3H]-Glycine overnight. Cells were
washed twice with ice cold PBS. Proteins were precipitated for
1 h with 10% TCA in a freezer. Precipitate was solved in 1 ml 1 M
NaOH. [3H]-Glycine incorporation was determined by scintillation
counting.
2.7. JNK activity assay
JNK activity assay was performed with the JNK activity assay kit
(Abcam). Cardiomyocytes were cultured on 6 cm dishes. 48 h after
Dpr1 siRNA transfection cells were stimulated with Wnt5a condi-
tioned medium for 5 h, washed three times with ice cold PBS and
lysed with 200 lL extraction buffer. Cleared lysates were obtained
for immunoprecipitaion with JNK speciﬁc antibodies combined
with protein A coated agarose beads. After washing precipitated
JNK was incubated together with its substrate c-jun and ATP’s for
4 h in 30 C. Supernatant of the mix was analyzed by Western blot.
2.8. Immunoﬂuorescence
For immunoﬂuorescence analysis, cardiomyocytes were ﬁxed
with 3.7% formaldehyde, permeabilized with 0.1% Triton-X
followed by incubation steps with the primary and secondary anti-
body (anti-Vangl2 antibody and anti-mouse FITC labeled antibody,
Santa Cruz). Co-immunostaining was performed with antibodies
against Dpr1 (Abcam; secondary antibody: goat anti-rabbit
FITC-labeled antibody, Abcam) and Vangl2 (Santa Cruz; secondary
antibody: sheep anti-mouse Cy3 labeled antibody, Sigma). For
counterstaining of DNAwe used Hoechst 33342 probes (Invitrogen).
The ﬂuorescence signals were detected and visualized by using a
Nikon A1Rsi 32 channel spectral imaging confocal laser scanning
system on a Nikon Ti inverted microscope and an Olympus BX51
ﬂuorescence microscope.
2.9. Statistical analysis
All data are reported as the mean ± S.D. Difference between the
groups was compared by a Wilcoxon-test or a 2-tailed Student t
test, when applicable. Signiﬁcance was accepted at the P < 0.05
level.
3. Results
3.1. Dpr1 depletion inhibits Wnt5a induced cardiomyocyte
hypertrophy
In primary cultures of isolated cardiomyocytes we evaluated
whether onset of non-canonical Wnt signaling induces features
of hypertrophy by stimulation with Wnt5a conditioned medium.
Compared to control cells we determined an increase of myocyte
surface area and protein synthesis inWnt5a treated cells indicating
2232 M. Hagenmueller et al. / FEBS Letters 588 (2014) 2230–2237that Wnt5a is sufﬁcient to trigger cardiomyocyte growth (Fig. 1A
and B). In order to examine to which extent Dpr1 contributes to
cardiomyocyte hypertrophy mediated by non-canonical Wnt sig-
naling we knocked down Dpr1. In Dpr1 depleted cells the hyper-
trophic effect of Wnt5a stimulation was inhibited indicating that
Dpr1 is required for Wnt5a induced hypertrophic growth which
links Dpr1 to the non-canonical Wnt signaling pathway in cardio-
myocytes (Fig. 1A and B).
3.2. Dpr1 is essential to activate the Wnt/PCP pathway
in cardiomyocytes
To gain more insight to the role of Dpr1 in non-canonical Wnt
transduction we assayed protein and phosphorylation levels of
JNK, PKC and CamK2 by Western blot upon overexpression or
knockdown of Dpr1 in isolated cardiomyocytes. Adenoviral overex-
pression of Dpr1 had no consequence on JNK, PKC and CamK2
expression or phosphorylation (Fig. 2A and B). However, we
observed a strong reduction of JNK phosphorylation in Dpr1
depleted cells (Fig. 2C and D). Of note, PKC and CamK2 expression
and phosphorylation was not effected (Fig. 2A–D). By means of
a JNK activity assay we examined whether transmission of
Wnt/PCP signals was blocked in Dpr1 depleted cells. Stimulation
with Wnt5a conditioned medium induced strong JNK activation
in control cells but failed to activate this kinase in cells lacking
Dpr1 all indicating that Dpr1 is essential to maintain and to induce
Wnt/PCP signaling (Fig. 2E and F).
3.3. Wnt5a induced cardiomyocyte hypertrophy requires JNK activity
The fact that Wnt/PCP pathway is blocked, in conjunction with
inhibition of Wnt5a induced hypertrophy in Dpr1 depleted cells
points to an essential role of JNK in non-canonical Wnt signaling
mediated cardiomyocyte growth. To prove this hypothesis we
incubated isolated cardiomyocytes with either DMSO or with
JNK inhibitor SP600125 [10 lM], stimulated the cells with Wnt5a
conditioned medium and assayed cell surface area and protein
synthesis. Both features of cardiomyocyte hypertrophy were
blocked in SP600125 treated cells indicating that JNK activity is
required for hypertrophic growth mediated by Wnt5a (Fig. 3A
and B).Fig. 1. Dpr1 depletion inhibits Wnt5a induced cardiomyocyte hypertrophy. (A) Bar g
inhibition of cardiomyocyte growth in Dpr1 knockdown cells. (B) Bar graph indicates W
blocked in Dpr1 depleted cells. (⁄P < 0.05 vs. unstimulated control; #P < 0.05 vs. Wnt5a st
nP 300 cells per group).3.4. Dpr1 depletion leads to accumulation of Vangl2 in perinuclear
located vesicles
To map the molecular mechanism of Wnt/PCP pathway inhibi-
tion in Dpr1 depleted cells we focused on the role of the trans-
membrane receptors ROR2 and Vangl2. Binding of Wnt ligand
Wnt5a to ROR induces the phosphorylation of Vangl2 and medi-
ates transduction of Wnt/PCP signals through JNK [11]. Adenoviral
over-expression of Dpr1 had no effect on ROR2 and Vangl2 levels
(Fig. 4A and B). Unexpectedly, we observed increased protein levels
of Vangl2 receptor in Dpr1 deﬁcient cells while expression of ROR2
remained unaltered (Fig. 4C and D). Unchanged Vangl2 mRNA
transcripts suggest a mechanism of stabilization which occurs
posttranscriptionally (Fig. 4E). To address this question we immu-
nostained Vangl2 in Dpr1 knockdown cardiomyocytes. While
Vangl2 localization in control cells was mainly in the membrane
and in the cytoplasm the situation in Dpr1 depleted cells was dif-
ferent. We observed a conspicuous accumulation of Vangl2 in ves-
icles located in perinuclear regions indicating that stabilization of
Vangl2 protein levels is a result of vesicular enrichment induced
by Dpr1 depletion (Fig. 4F). Moreover, co-immunostaining of
Dpr1 and Vangl2 in untreated, isolated cardiomyocytes revealed
a co-localization in perinuclear areas but not in the cytoplasm
and in regions of the cell membrane (Fig. 4G).
3.5. Members of the Wnt/PCP pathway are upregulated in a rat model
of myocardial infarction
In a recently published study we have shown a robust overex-
pression of Dpr1 in the remote area (vital area) of left ventricular
tissue obtained from a rat myocardial infarction (MI) model, 1 week
after induction of MI [12]. By immunoblotting the same protein
lysates we observed increased protein levels of the ligand Wnt5a
and the Wnt/PCP membrane receptors ROR2 and Vangl2 (Fig. 5A
and B). Moreover, mRNA copy numbers of these receptors were
upregulated compared to sham operated mice suggesting that the
ROR2/Vangl2 axis plays an important role in the remodeling pro-
cess after MI and underlining the relevance of the ﬁndings above
in a cardio-pathological context. Interestingly, mRNA expression
of the Wnt ligand Wnt5a remained stable indicating that Wnt5a
secretion occurs in another area of the infarcted heart (Fig. 5C).raph shows an increase in myocyte surface area following Wnt5a treatment and
nt5a induced increase of protein synthesis in cardiomyocytes. Protein synthesis is
imulated control; all experiment were performed at least three times in triplicates;
Fig. 2. Dpr1 is essential to activate Wnt/PCP pathway in cardiomyocytes. (A and B) Representative Western blots of cardiomyocyte protein lysates reveals no difference in
total- and phospho-JNK, -PKCa and -CamK2 abundance between control cells and Dpr1 overexpressed cells. (C and D) Representative Western blots of cardiomyocyte protein
lysates show no difference in levels of total- and phophorylated PKCa- and CamK2 between control and Dpr1 depleted cells. Phosphorylation of JNK decreases dramatically
following Dpr1 knockout. (E and F) Western blot result of a JNK activity assay. Wnt5a induced activation of JNK increases levels of phosphorylated c-junSer73. Activation of JNK
is completely blocked in Dpr1 depleted cardiomyocytes. (⁄P < 0.05 vs. unstimulated control; #P < 0.05 vs. Wnt5a stimulated control; experiments were performed three times
in duplicates).
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Here, we provide evidence that Wnt5a induced cardiomyocyte
hypertrophy is inhibited in Dpr1 depleted cells, coupling Dpr1 to
non-canonical Wnt signaling. Wnt5a is the most investigated
non-canonical Wnt ligand and is implicated in a variety of different
Wnt aspects [15]. Since Wnt5a activates not only Wnt/PCP signal-
ing it is not unambiguous which of the non-canonical Wnt branch
is responsible for cardiomyocyte growth. However, given the resultof inhibited Wnt/PCP pathway in Dpr1 knockdown cells and the
inhibition of Wnt5a induced cardiomyocyte hypertrophy in cells
treated with the JNK inhibitor SP600125 we propose that reduced
cell surface area and protein synthesis is a result of the blocked
Vangl2/JNK axis. The implication of JNK in cardiac hypertrophy
was ﬁrst demonstrated byWang et al. [16]. Unlike our experiments
they induced JNK activation by over-expression of dual-speciﬁc-
mitogen-activated-protein-kinase-kinase-7 (MKK-7) which is
located upstream of JNK. In agreement with our ﬁndings they
Fig. 3. JNK inhibition blocks Wnt5a induced cardiomyocyte hypertrophy. (A) Bar graph shows an increase in myocyte surface area following Wnt5a treatment and inhibition
of cardiomyocyte growth in SP600125 treated cells. (B) Bar graph indicates Wnt5a induced increase of protein synthesis in cardiomyocytes. Protein synthesis is blocked in
SP600125 treated cells. (⁄P < 0.05 vs. unstimulated control; #P < 0.05 vs. Wnt5a stimulated control; all experiment were performed at least three times in triplicates; nP 300
cells per group).
2234 M. Hagenmueller et al. / FEBS Letters 588 (2014) 2230–2237observed several features of cardiomyocyte hypertrophy such as
increased cell surface area, protein synthesis and ANF expression.
However, the effect of JNK inhibition on suppression of hypertro-
phy was not investigated in their study. Subsequent publications
revealed a more controversial and complex role of JNK in the con-
text of cardiac diseases. Chronic treatment of cardiomyopathic
Bio14.6 hamsters with JNK inhibitor SP600125 aggravates LV
chamber dilation and LV dysfunction [17]. In contrast, but
consistently with our study, the group of Wu et al. observed
improvement of cardiac function and decreased ﬁbrosis in cardio-
myopathy caused by mutation in the lamin A/C gene by using the
same JNK inhibitor [18].
Moreover, by performing knockdown experiments in isolated
cardiomyocytes we identiﬁed Dpr1 as an essential regulator to
maintain and to trigger non-canonical Wnt/PCP signaling. In
Dpr1 depleted cells Wnt5a induced activation of JNK was com-
pletely blocked. The contribution of Dpr1 in Wnt/PCP signaling
was described in earlier studies. Wen et al. established a global
homozygote Dpr1 knockout mouse model. These animal exhibit
neural tube defects accompanied by severe posterior malforma-
tions all indicating deregulation of the Wnt/PCP pathway which
is considered to organize neural tube development [19]. JNK and
the Ras homologue guanosine triphosphatase (Rho GTPase) are
two among several Wnt/PCP effectors [20,21]. Contradictory to
our observations, in Dpr1/ mouse embryonic ﬁbroblasts (MEF)
Wnt/PCP deregulation was associated with higher JNK activity
but lower activity of Rho GTPase. An explanation could be cell
and context dependent functions of Dpr1. It is possible that activa-
tion of JNK substitutes Rho GTPase activity in Dpr1 depleted MEF’s.
Suriben et al. discovered an association between Dpr1, Dvl2 and
the four-span-trans-membrane receptor Vangl2 in regulating the
Wnt/PCP pathway. Similar to the study of Wen et al. they estab-
lished a mouse model with homozygous mutation for Dpr1. The
group observed the same phenotypes accompanied by deregula-
tion of the Wnt/PCP pathway. They provide evidence that Dpr1 is
a crucial regulator of Vangl2 in the development of the primitive
streak. On molecular levels they discovered genetic interaction of
Dpr1 and Vangl2 [22]. In agreement with our study they identiﬁed
post-translational stabilization of Vangl2 in the primitive streak of
their Dpr1/ mouse model. Furthermore, they showed that Dpr1
forms complexes with Vangl2 and Dvl2 in HEK293 cells. This inter-
action occurs with different binding domains of Dpr1 and bindingof Dpr1 to Vangl2 is independent of Dvl2. Remarkably and congru-
ent to the study of Wen et al. deregulation of Wnt/PCP signaling in
Dpr1/was associated with higher JNK activity. In our study, Dpr1
depletion led to decreased phosphorylation of JNK under basal con-
ditions and complete inhibition of Wnt5a induced JNK activation.
Gao et al. demonstrated that binding of Wnt5a to ROR2 induces
a complex formation of Ror2 and Vangl2 followed by phosphoryla-
tion of Vangl2 on multiple Serine/Threonin residues. Increased
phosphorylation leads to higher activity which is subsequently fol-
lowed by activation of JNK [11].
In Dpr1 deﬁcient cardiomyocytes we observed stabilized
Vangl2 proteins enriched in perinuclear vesicles. We hypothesize
that depletion of Dpr1 blocks Vangl2 carriage to the membrane.
As a result, Vangl2 cannot be recruited for ROR2 mediated phos-
phorylation and therefore Wnt5a induced activation of the Wnt/
PCP pathway is blocked (Fig. 6). However, the present study does
not elucidate in detail how Dpr1 depletion impairs Vangl2 mem-
brane trafﬁcking mechanistically. Since co-localization of Dpr1
and Vangl2 was observed only in perinuclear regions but not in
areas near the cell membrane, it is likely that Vangl2 requires
another molecular player for membrane trafﬁcking and it can be
excluded that this process occurs through direct interaction with
Dpr1 alone.
A further limitation of the present study is the lack of siRNA or
commercial available inhibitors which successfully target Vangl2
to investigate the precise role of Vangl2 in Wnt5a signaling trans-
duction and concomitant cardiomyocyte hypertrophy. However,
upregulation of Wnt5a and the membrane receptors ROR2 and
Vangl2 in the remote area of left ventricular tissue obtained from
a rat MI model suggests an involvement of the Wnt/PCP pathway
in a cardio-pathological context. This ﬁnding supports our
in vitro hypothesis since both receptors are activated by binding
of the Wnt ligand Wnt5a to ROR2 [11]. In addition, we have previ-
ously described an upregulation of Dpr-1 protein and mRNA levels
in the same protein lysates [12]. It is still an open question where
the Wnt ligands come from. Although we have observed more
Wnt5a proteins in the remote area of left ventricular MI tissue, lev-
els of Wnt5a mRNA copy numbers remained stable, indicating that
expression and secretion of this ligand occurs in another area of the
infarcted heart.
In conclusion, our data suggest a novel role for Dpr1 and the
Wnt/PCP pathway in cardiomyocyte hypertrophy mediated by
Fig. 4. Dpr1 depletion leads to accumulation of Vangl2 in perinuclear located vesicles. (A and B) Representative Western blot of cardiomyocyte lysates shows no difference in
protein amount of ROR2 and Vangl2 between control and Dpr1 overexpressed cells. (C and D) Representative Western blots of cardiomyocyte lysates with ROR2 and Vangl2
speciﬁc antibodies. A robust increase of Vangl2 protein amount in Dpr1 depleted cells was observed while expression of ROR2 was unaffected. (E) ROR2 and Vangl2 mRNA
copy numbers remained stable in Dpr1 deﬁcient cells. (F) Confocal microscope image of cardiomyocytes transfected with unspeciﬁc or Dpr1 siRNA. Cells were immunostained
with Vangl2 speciﬁc antibodies (green) and counterstained with Hoechst 33342. Dpr1 depleted cells display accumulation of Vangl2 in perinuclear regions (arrows). (G) Co-
immunostaining of cardiomyocyte with speciﬁc antibodies against Dpr1 (green) and Vangl2 (red) reveals co-localization in perinuclear regions (arrows) but not in membrane
areas. Cells were counterstained with Hoechst 33342. (⁄P < 0.05 vs. control; n.s. not signiﬁcant, experiments were done three times in duplicates).
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Fig. 5. Members of the Wnt/PCP pathway are upregulated in a rat model of myocardial infarction. (A and B) Immunoblots and quantiﬁcation of tissue lysates prepared from
the remote area of the left ventricle of a rat MI model shows upregulation of the Wnt/PCP-pathway members Wnt5a, ROR2 and Vangl2. Coomassie staining of the membranes
used was performed as a loading control. (C) mRNA levels of ROR2 and Vangl2 but not of Wnt5a were increased in the remote area of the left ventricular tissue of a rat MI
model. (⁄P < 0.05 vs. control; n.s. not signiﬁcant, n = 6 in sham operated rats, n = 8 in MI rats).
Fig. 6. Suggested role of Dpr1 in Wnt/PCP-pathway in cardiomyocytes. Binding of
Wnt5a to ROR induces the phosphorylation of Vangl2. In turn Vangl2 mediates the
activation of JNK-pathway. Here, Dpr1 is involved in Vangl2 membrane transport.
Following Dpr1 depletion Vangl2 membrane transport is blocked. As a result Vangl2
is physically not present for Wnt5a/ROR2 induced phosphorylation and JNK cannot
be activated.
2236 M. Hagenmueller et al. / FEBS Letters 588 (2014) 2230–2237Wnt5a and provide a promising starting point for a potential novel
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